In this section:

07 May 2018

UPDATE: SMC Publishes Advice on Brodalumab (Kyntheum) for Psoriasis

On 11th December 2017, the Scottish Medicines Consortium (SMC) published its decision to not recommend brodalumab (Kyntheum) for the treatment of severe psoriasis.

Brodalumab blocks the activity of interleukin 17A (IL-17A), a chemical ’messenger’ in the immune system that signals other cells to cause inflammation. In people with psoriasis the immune system is overactive and creates too much inflammation, which leads to the development of psoriasis symptoms. By blocking IL-17A, brodalumab (Kyntheum) aims to prevent some of that inflammation from occurring, leading to an improvement in psoriasis for some people who take it. Other biologic medications that block the activity of IL-17A, called Cosentyx (secukinumab) and Taltz (ixekizumab) are currently available for people with severe psoriasis.

You can read the full, detailed decision from the SMC here.


After an appeal and re-assessment of evidence, the SMC has accepted brodalumab (Kyntheum) to treat severe psoriasis, where people have not had adequate results from conventional systemic treatments, or cannot take them. This brings the availability of brodalumab (Kyntheum) in Scotland into alignment with the decision taken by NICE for England and Wales in March.

The Psoriasis Association is the UK's leading national charity and membership organisation for people affected by psoriasis – patients, families, carers and health professionals Read More >

Get in touch

The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF


Tel :
01604 251 620
Fax :
01604 251 621
Registered with Fundraising Regulator -

© The Psoriasis Association Charitable Incorporated Organisation Number: 1180666 Scotland: SC039886 Privacy PolicyCookies

Site by Spoken Image | glitterfish

We use cookies to help us provide you with a better service, but do not track anything that can be used to personally identify you.

If you prefer us not to set these cookies, please visit our Cookie Settings page or continue browsing our site to accept them.